

Press Release

for Immediate Release

Q2FY26 Revenue from operations at INR 12,970 Mn up 34% YoY, EBITDA at INR 2,782 Mn up 37% YoY, PBT at INR 1,759 Mn up 37% YoY, PAT at INR 1,306 Mn up 34% YoY.

Hyderabad, India, November 13, 2025: Granules India Ltd., a vertically integrated pharmaceutical company, today announced its financial results for the quarter ended September 30, 2025.

Financial Summary (All numbers in INR Mn)

QUARTERLY CONSOLIDATED FINANCIALS	Q2FY26	Q1FY26	Growth (QoQ)	Q2FY25	Growth (YoY)
Revenue from Operations	12,970	12,101	7%	9,666	34%
EBITDA before exceptional items	2,782	2,467	13%	2,033	37%
EBITDA %	21%	20%		21%	
PBT before exceptional items	1,759	1,704	3%	1,284	37%
PAT	1,306	1,126	16%	972	34%
PAT %	10%	9%		10%	

Financial and Business Summary for Q2FY26

- Revenue from Operations of Q2FY26 stood at INR 12,970 Mn, a growth of 34% YoY across regions
- Finished dosages (FD), Active Pharmaceuticals Ingredients (API), Pharmaceutical Formulation Intermediates (PFI), and Peptides/ CDMO contribute 74%, 13%, 10% and 2% of revenue from operations respectively for Q2FY26.
- ROCE is at 16.2% (Post Acquisition of Senn Chemicals AG) as compared to 16.9% YoY.
- Net debt stood at INR 10,241 Mn and Net debt to EBITDA at 0.98x.

Commenting on the results, Dr. Krishna Prasad Chigurupati, Chairman & Managing Director of Granules India Limited said, “We are delighted to deliver a resilient financial performance with healthy growth in both revenue and profitability. The improvement in EBITDA and PAT reflects our continued focus on operational excellence, disciplined execution, and the strength of our governance. Our ongoing investments in R&D and talent underscore our commitment to innovation and long-term value creation. Our peptides CDMO platform through Ascelis, anchored in the legacy of Senn Chemicals in Switzerland, is steadily gaining visibility, with renewed customer interest and promising new discussions underway.”

About Granules India Ltd. (BSE: 532482, NSE: GRANULES)

Granules India Limited, incorporated in 1991 is a vertically integrated fast growing Indian pharmaceutical company headquartered at Hyderabad with best-in-class facilities and commitment to operational excellence, quality, and customer service. We are among the few pharmaceutical companies in the world to be present in the manufacturing of entire value chain – from Active Pharmaceutical Ingredients (APIs), Pharmaceutical Formulation Intermediates (PFIs), Finished Dosages (FDs) and Peptides CDMO. Our products are being distributed to over 300+ customers in regulated and semi-regulated markets with a global presence extending to over 80+ countries with offices across India, US, and UK. The Company has 11 manufacturing facilities out of which 8 are in India, 2 in the USA and 1 in Switzerland and has regulatory approvals from US FDA, EDQM, EU GMP, COFEPRIS, WHO GMP, TGA, K FDA, DEA, MCC, and HALAL.

Safe Harbor

This document includes certain forward-looking statements. These statements are based on management's current expectations or beliefs and are subject to uncertainty and changes in circumstances. Actual results may vary materially from those expressed or implied by the statements herein due to changes in economic, business, competitive, technological, and/or regulatory factors. Granules India Ltd., its directors, and any of the affiliates or employees are under no obligation to and expressly disclaims any such obligation to, update or alter its forward-looking statements, whether as a result of new information, future events, or otherwise.

Contacts:	
Granules IR Desk investorrelations@granulesindia.com	Chaitanya Tummala Company Secretary chaitanya.tummala@granulesindia.com